ChromaCode and Protean BioDiagnostics Establish Strategic Partnership to Introduce a HDPCR-based NSCLC Assay in the U.S.


Street Insider:

CARLSBAD, Calif.Aug. 10, 2023 /PRNewswire/ — ChromaCode, Inc., a genomics multiplexing platform company developing accessible and affordable solutions for laboratories, patients, and physicians, today announced a strategic partnership with Protean BioDiagnostics Inc., a CAP/CLIA-accredited, high-complexity laboratory specializing in developing and commercializing advanced cancer diagnostic technologies. This partnership’s goal is to introduce a non-small cell lung cancer (NSCLC) assay, based on ChromaCode’s state-of-the-art High Definition PCR (HDPCR™) multiplexing technology, via an early access program.

View full article

More Articles Here